220 related articles for article (PubMed ID: 26043272)
41. Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.
Aimi T; Suzuki K; Hoshino T; Mizushima T
J Neurochem; 2015 Aug; 134(4):611-7. PubMed ID: 25963375
[TBL] [Abstract][Full Text] [Related]
42. Glycosylphosphatidylinositols: More than just an anchor?
Bate C; Nolan W; Williams A
Commun Integr Biol; 2016; 9(2):e1149671. PubMed ID: 27195066
[TBL] [Abstract][Full Text] [Related]
43. Cellular prion protein neither binds to alpha-synuclein oligomers nor mediates their detrimental effects.
La Vitola P; Beeg M; Balducci C; Santamaria G; Restelli E; Colombo L; Caldinelli L; Pollegioni L; Gobbi M; Chiesa R; Forloni G
Brain; 2019 Feb; 142(2):249-254. PubMed ID: 30601948
[TBL] [Abstract][Full Text] [Related]
44. The inside-out amyloid hypothesis and synapse pathology in Alzheimer's disease.
Gouras GK; Willén K; Faideau M
Neurodegener Dis; 2014; 13(2-3):142-6. PubMed ID: 24080821
[TBL] [Abstract][Full Text] [Related]
45. Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.
Viola KL; Klein WL
Acta Neuropathol; 2015 Feb; 129(2):183-206. PubMed ID: 25604547
[TBL] [Abstract][Full Text] [Related]
46. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway.
Malaplate-Armand C; Florent-Béchard S; Youssef I; Koziel V; Sponne I; Kriem B; Leininger-Muller B; Olivier JL; Oster T; Pillot T
Neurobiol Dis; 2006 Jul; 23(1):178-89. PubMed ID: 16626961
[TBL] [Abstract][Full Text] [Related]
47. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
[TBL] [Abstract][Full Text] [Related]
48. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.
Atsmon-Raz Y; Miller Y
ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553
[TBL] [Abstract][Full Text] [Related]
49. Calcium-Sensing Receptor Mediates β-Amyloid-Induced Synaptic Formation Impairment and Cognitive Deficits
Feng C; Bao X; Shan L; Ling Y; Ding Y; Wang J; Cao Y; Wang Q; Cui W; Xu S
Front Aging Neurosci; 2020; 12():144. PubMed ID: 32670047
[TBL] [Abstract][Full Text] [Related]
50. Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer's Disease.
Dinamarca MC; Ríos JA; Inestrosa NC
Front Physiol; 2012; 3():464. PubMed ID: 23267328
[TBL] [Abstract][Full Text] [Related]
51. Beta-amyloid oligomers affect the structure and function of the postsynaptic region: role of the Wnt signaling pathway.
Dinamarca MC; Colombres M; Cerpa W; Bonansco C; Inestrosa NC
Neurodegener Dis; 2008; 5(3-4):149-52. PubMed ID: 18322375
[TBL] [Abstract][Full Text] [Related]
52. Intraneuronal Aβ accumulation, amyloid plaques, and synapse pathology in Alzheimer's disease.
Capetillo-Zarate E; Gracia L; Tampellini D; Gouras GK
Neurodegener Dis; 2012; 10(1-4):56-9. PubMed ID: 22269167
[TBL] [Abstract][Full Text] [Related]
53. Prion protein expression in senile plaques in Alzheimer's disease.
Ferrer I; Blanco R; Carmona M; Puig B; Ribera R; Rey MJ; Ribalta T
Acta Neuropathol; 2001 Jan; 101(1):49-56. PubMed ID: 11194941
[TBL] [Abstract][Full Text] [Related]
54. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
[TBL] [Abstract][Full Text] [Related]
55. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
56. Heterogeneous Association of Alzheimer's Disease-Linked Amyloid-β and Amyloid-β Protein Precursor with Synapses.
Willén K; Sroka A; Takahashi RH; Gouras GK
J Alzheimers Dis; 2017; 60(2):511-524. PubMed ID: 28869466
[TBL] [Abstract][Full Text] [Related]
57. Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A
Palavicini JP; Wang C; Chen L; Hosang K; Wang J; Tomiyama T; Mori H; Han X
Acta Neuropathol Commun; 2017 Jul; 5(1):56. PubMed ID: 28750656
[TBL] [Abstract][Full Text] [Related]
58. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
59. Structure of amyloid oligomers and their mechanisms of toxicities: Targeting amyloid oligomers using novel therapeutic approaches.
Salahuddin P; Fatima MT; Abdelhameed AS; Nusrat S; Khan RH
Eur J Med Chem; 2016 May; 114():41-58. PubMed ID: 26974374
[TBL] [Abstract][Full Text] [Related]
60. Beta-amyloid, neuronal death and Alzheimer's disease.
Carter J; Lippa CF
Curr Mol Med; 2001 Dec; 1(6):733-7. PubMed ID: 11899259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
